Article Text

IgM-rheumatoid factor and anti-cyclic citrullinated peptide decrease by 50% during intensive treatment in early rheumatoid arthritis
  1. L H D van Tuyl1,
  2. W F Lems2,
  3. P J S M Kerstens3,
  4. A E Voskuyl2,
  5. B A C Dijkmans2,
  6. M Boers1
  1. 1
    VU University Medical Center, Department of Clinical Epidemiology & Biostatistics, Amsterdam, The Netherlands
  2. 2
    VU University Medical Center, Rheumatology, Amsterdam, The Netherlands
  3. 3
    Jan van Breemen Institute, Amsterdam, The Netherlands
  1. Correspondence to L H D van Tuyl, VU University Medical Center, Department of Clinical Epidemiology & Biostatistics, PK 6Z 159, PO Box 7057, 1007 MB Amsterdam, The Netherlands; L.vantuyl{at}

Statistics from

Decreases in rheumatoid factor (IgM-RF) during antirheumatic treatment are often reported,1 2 3 4 but the course of anti-cyclic citrullinated peptide (anti-CCP) is less conclusive, with some studies showing decrease,2 5 6 but others finding no change.4 7 8

As anti-CCP antibodies are very specific as a marker for rheumatoid arthritis (RA), decreases in anti-CCP levels on therapy may have prognostic relevance and guide further treatment decisions in patients with early RA.

A total of 21 patients with active, early RA were treated for 40 weeks with intensive conventional disease-modifying antirheumatic drug (DMARD) therapy, comprising hydroxychloroquine, sulfasalazine, methotrexate and tapered high-dose prednisolone (enhanced “COBRA” (Combinatietherapie Bij Reumatoide Artritis trial) schedule, fig 1). On non-response at 8 weeks, methotrexate (MTX)was intensified to 25 mg/week; on non-response at 21 weeks, infliximab was offered to patients on high-dose MTX and MTX was intensified in the remainder. Serum was available for 18 out of 21 patients.

Figure 1

Top: percentage change of …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.